IMV Inc. (TSX:IMV) (OTCQX:IMMVD), a clinical stage immunotherapy company, today announced that its common shares have been approved for listing on the Nasdaq Capital Market under the symbol “IMV.” Trading will commence as early as Friday, June 1, 2018. The Corporation will retain its listing on the Toronto Stock Exchange under the symbol “IMV” and the company’s common shares will continue to trade on the OTCQX under the symbol “IMMVD” until trading on the Nasdaq commences.
Frederic Ors, IMV Chief Executive Officer, commented, “On the heels of recent progress we have made in positioning and validating IMV’s unique value proposition in immuno-oncology, listing on Nasdaq affords us the opportunity to attract more institutional investors, broaden our shareholder base, and improve liquidity. We celebrate this milestone and look forward to continuing our track record of clinical progress and corporate advancement.”
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. Connect at www.imv-inc.com.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
Read Next
